Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABSALON
2024-518510-87-00Phase 4Authorised
- Sponsor
- Rigshospitalet
- Start
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in open-angle glaucoma (OAG) comparing Oral semaglutide (Rybelsus) with Placebo (2 arms). Planned start Nov 2024; status: authorised.
02
Drugs
03
Conditions
open-angle glaucoma (OAG)
Beyond the preview
Go deeper on 2024-518510-87-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518510-87-00.